BullFrog AI Holdings, Inc. announced that it has identified multiple potential therapeutic targets, including three novel targets, for colorectal cancer using the Company's proprietary AI-driven platform, bfLEAP??. The newly identified targets will be validated through BullFrog AI's ongoing collaboration with the J. Craig Venter Institute (JCVI), a genomics research and innovation institution.JCVI will utilize its expertise in target validation and functional genomic screening to further investigate the potential of these targets in colorectal cancer.